28th May 2014 07:00
Issued: 27 May 2014, London UK - LSE announcement
Serious Fraud Office Investigation
GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK's Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group's commercial practices.
GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO.
V A Whyte
Company Secretary
27 May 2014
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
GSK enquiries: | |||
UK Media enquiries: | David Mawdsley | +44 (0) 20 8047 5502 | (London) |
Simon Steel | +44 (0) 20 8047 5502 | (London) | |
US Media enquiries: | Stephen Rea | +1 215 751 4394 | (Philadelphia) |
Analyst/Investor enquiries: | Ziba Shamsi | +44 (0) 20 8047 5543 | (London) |
Kirsty Collins (SRI & CG) | +44 (0) 20 8047 5534 | (London) | |
Tom Curry | + 1 215 751 5419 | (Philadelphia) | |
Gary Davies | +44 (0) 20 8047 5503 | (London) | |
James Dodwell | +44 (0) 20 8047 2406 | (London) | |
Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
Lucy Singah | +44 (0) 20 8047 2248 | (London) |
Related Shares:
Glaxosmithkline